Matthew Luchini

Stock Analyst at BMO Capital

(2.04)
# 3,062
Out of 5,044 analysts
34
Total ratings
44.44%
Success rate
6.45%
Average return

Stocks Rated by Matthew Luchini

Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51$30
Current: $10.21
Upside: +193.83%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $2.36
Upside: +7,950.85%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89$69
Current: $30.05
Upside: +129.62%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138$104
Current: $18.93
Upside: +449.39%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $2.51
Upside: +2,091.24%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $9.59
Upside: +953.18%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $652.91
Upside: -3.51%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119$124
Current: $421.60
Upside: -70.59%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74$64
Current: $118.50
Upside: -45.99%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $35.22
Upside: -60.25%
Downgrades: Market Perform
Price Target: $47$60
Current: $1.43
Upside: +4,095.80%